Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines
International Journal of Molecular Sciences · 10.02.2023 · 24 (4) · 3553
DOI: 10.3390/ijms24043553 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.02.2023. Verfasst von Monika M Kutyna und 5 weiteren Autor:innen. Beteiligte Einrichtung: Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia. Hauptthemen laut MEDLINE: Azacitidine, Drug Resistance, Neoplasm, Equilibrative Nucleoside Transporter 1, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb Australia, Royal Adelaide Hospital, South Australia Health and Medical Research Institute.
Abstract (Originalsprache)
Azacitidine (AZA) is commonly used hypomethylating agent for higher risk myelodysplastic syndromes and acute myeloid leukemia (AML). Although some patients achieve remission, eventually most patients fail AZA therapy. Comprehensive analysis of intracellular uptake and retention (IUR) of carbon-labeled AZA (14C-AZA), gene expression, transporter pump activity with or without inhibitors, and cytotoxicity in naïve and resistant cell lines provided insight into the mechanism of AZA resistance. AML cell lines were exposed to increasing concentrations of AZA to create resistant clones. 14C-AZA IUR was significantly lower in MOLM-13- (1.65 ± 0.08 ng vs. 5.79 ± 0.18 ng; p < 0.0001) and SKM-1- (1.10 ± 0.08 vs. 5.08 ± 0.26 ng; p < 0.0001) resistant cells compared to respective parental cells. Importantly, 14C-AZA IUR progressively reduced with downregulation of SLC29A1 expression in MOLM-13- and SKM-1-resistant cells. Furthermore, nitrobenzyl mercaptopurine riboside, an SLC29A inhibitor, reduced 14C-AZA IUR in MOLM-13 (5.79 ± 0.18 vs. 2.07 ± 0.23, p < 0.0001) and SKM-1-naive cells (5.08 ± 2.59 vs. 1.39 ± 0.19, p = 0.0002) and reduced efficacy of AZA. As the expression of cellular efflux pumps such as ABCB1 and ABCG2 did not change in AZA-resistant cells, they are unlikely contribute to AZA resistance. Therefore, the current study provides a causal link between in vitro AZA resistance and downregulation of cellular influx transporter SLC29A1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia.
- Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia.
- Department of Haematology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
- Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA 5000, Australia.
ORCID-Profile: Deborah L White, Chung H Kok
Förderung
- Bristol-Myers Squibb Australia
- Royal Adelaide Hospital
- South Australia Health and Medical Research Institute
- NHMRC and Beat Cancer Fellowships
- National Health and Medical Research Council Medical Research Future Fund
- Cancer Australia
- Leukaemia Foundation of Australia
Zitieren
APA
Kutyna, M. M., Loone, S., Saunders, V. A., White, D. L., Kok, C. H., & Hiwase, D. K. (2023). Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines. International Journal of Molecular Sciences, 24(4), 3553. https://doi.org/10.3390/ijms24043553
Vancouver
Kutyna MM, Loone S, Saunders VA, White DL, Kok CH, Hiwase DK. Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines. International Journal of Molecular Sciences. 2023;24(4):3553. doi:10.3390/ijms24043553
BibTeX
@article{Kutyna2023,
author = {Kutyna, Monika M and Loone, Sophie and Saunders, Verity A and White, Deborah L and Kok, Chung H and Hiwase, Devendra K},
title = {Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {4},
pages = {3553},
doi = {10.3390/ijms24043553}
}
EUVIMED